A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 14,937 shares of NVCT stock, worth $109,040. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,937
Holding current value
$109,040
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$5.98 - $8.25 $89,323 - $123,230
14,937 New
14,937 $94,000
Q2 2023

Aug 14, 2023

BUY
$12.62 - $18.4 $353,713 - $515,715
28,028 New
28,028 $447,000

Others Institutions Holding NVCT

About Nuvectis Pharma, Inc.


  • Ticker NVCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,642,500
  • Market Cap $107M
  • Description
  • Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...
More about NVCT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.